Doxazosin in the current treatment of hypertension

  title={Doxazosin in the current treatment of hypertension},
  author={Andrzej Wykrętowicz and Przemysław Guzik and Henryk Wysocki},
  journal={Expert Opinion on Pharmacotherapy},
  pages={625 - 633}
Background: Evidence from various studies has shown that even a very small reduction in the blood pressure explains the majority of benefits in cardiovascular outcomes. Although doxazosin is a relatively old drug, it is a very effective add-on therapeutic agent. It has been used in a variety of clinical trials, including different groups of hypertensive patients such as diabetics, the elderly, patients with benign prostatic hyperplasia or hypercholesterolaemia, the obese or Afro-Americans and… 

Evaluation of the Effects of Prazosin on Resistant Diastolic Hypertension With a Focus on Sex Difference

Low-dose prazosin as an additional drug to other major antihypertensive drugs with minor and transient complications can be reliably effective in reducing resistant DBP.

Overview of Alpha-blockers in Hypertension: Reappraisal of Perspectives.

This drug which went into hibernation over the decades, increasing understanding of the positive metabolic effects and ideal hemodynamic effects of “alpha-blockers” developed over 45 years ago has prompted us to review this drug.

A Review of Antihypertensive Drugs and Choosing the Right Antihypertensive for Recurrent Stroke Prevention

The etiology of long-standing hypertension is generally multifactorial and very poorly appreciated in the individual patient, and background issues interface with the well-established need for antihypertensive therapy as an important component of secondary stroke reduction.

Linear pharmacokinetics of doxazosin in healthy subjects

Statistical analysis of doxazosin pharmacokinetic parameters obtained after administration of the investigated dose ranges 2-8 mg demonstrated linear pharmacokinetics.

Novel Anti-Inflammatory Effects of Doxazosin in Rodent Models of Inflammation

In animals challenged systemically and intranasally with LPS, doxazosin inhibited TNF-α and MCP-1 production, respectively, and in the delayed-type hypersensitivity model, footpad swelling was inhibited by doxAZosin.

Effect of 3 Months of Doxazosin Therapy on T-Cell Subsets in Type 2 Diabetic Patients

Results indicate an immunomodulatory action of doxazosin in type 2 diabetic patients, and patients' blood pressure, blood glucose control and lipid profiles all significantly improved.

Medicine-use evaluation of doxazosin prescribing to inform formulary recommendations.

MUEs offer a distinct, cost-effective approach to improve medicine use in all settings and can be beneficial to inform formulary changes and re-evaluate medication-use restrictions.



Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.

It is suggested that addition of a low dose of the alpha(1)-blocker doxazosin effectively reduces BP in patients taking CCBs and ARBs or ACE inhibitors, and seems to be useful as a third-line antihypertensive drug.

Usefulness of the α1-Blocker Doxazosin as a Third-Line Antihypertensive Drug

Investigation of the efficacy of a low dose of an α1-blocker added to combination therapy with CCBs and either ARBs or ACE inhibitors for the treatment of hypertension suggests that doxazosin seems to be useful as a third-line antihypertensive drug.

Clinical Usefulness of Doxazosin in Patients with Type 2 Diabetes Complicated by Hypertension: Effects on Glucose and Lipid Metabolism

The beneficial effects of doxazosin on blood pressure and lipid and glucose metabolism shown in this study suggest that this drug is clinically useful as an anti-hypertensive agent for patients with diabetes.

Doxazosin as Combination Therapy for Patients with Stage 1 and Stage 2 Hypertension

  • H. Black
  • Medicine
    Journal of cardiovascular pharmacology
  • 2003
The studies described demonstrate that doxazosin is effective as combination therapy for patients with stage 1 and stage 2 hypertension and for patients who have concomitant hyperlipidemia or glucose intolerance.

Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension.

Alpha-blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension

The use of an active drug for a run-in period may be a useful design for permitting the study of patients from whom all treatment cannot safely be withdrawn, and should be useful for resistant hypertensives who have not tolerated P-blockade or ACE inhibitors.